NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma”...
Month: April 2023
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
Horus to increase ILUVIEN commercial presence with Nordic Retinal SpecialistsATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:...
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company,...
ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trialMADRID, Spain and BOSTON, April...
PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates
REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused...
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2...
Corcept Therapeutics Announces Preliminary Results of Tender Offer
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the...
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to...
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction...
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
Common Stock Offering Priced At-The-MarketIRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active controlSAN DIEGO, April 01, 2023...
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering
New York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company...
Mydecine Reports Financial Results for the Year Ended December 2022
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update
Revenue increased 14% annually driven by greater adoption of medical treatments. BRENTWOOD, Tenn., March 31, 2023 (GLOBE NEWSWIRE) -- IMAC...
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of...
Aridis Provides Corporate Update
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...